Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Oppenheimer Analyst Says

Gilead Sciences (NASDAQ:GILD) had its target price upped by investment analysts at Oppenheimer from $115.00 to $132.00 in a research note issued to investors on Tuesday,Briefing.com Automated Import reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Oppenheimer’s price objective indicates a potential upside of 13.80% from the stock’s previous close.

Several other equities analysts have also recently issued reports on GILD. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Morgan Stanley increased their price objective on Gilead Sciences from $113.00 to $123.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Wells Fargo & Company lifted their target price on Gilead Sciences from $105.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Royal Bank of Canada increased their price target on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. Finally, Piper Sandler raised their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $102.76.

Gilead Sciences Trading Up 1.5 %

Shares of GILD stock opened at $115.99 on Tuesday. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $117.16. The stock’s fifty day simple moving average is $97.87 and its 200 day simple moving average is $90.45. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $144.55 billion, a P/E ratio of 313.49, a P/E/G ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, sell-side analysts predict that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $17,597,559.49. This trade represents a 1.46 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 293,356 shares of company stock worth $29,166,240 in the last quarter. Insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in GILD. HHM Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences in the 4th quarter valued at $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at $29,000. Crews Bank & Trust bought a new stake in shares of Gilead Sciences during the 4th quarter worth $31,000. Finally, Stephens Consulting LLC grew its position in Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 260 shares during the period. 83.67% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.